Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1963 Apr;26(2):111–122. doi: 10.1136/jnnp.26.2.111

A trial of therapy by nucleosides and nucleotides in muscular dystrophy

W H S Thomson 1,2,1, Kenneth E Guest 1,2
PMCID: PMC495546  PMID: 13981251

Full text

PDF
111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALLEN J. E., RODGIN D. W. Mental retardation in association with progressive dystrophy. Am J Dis Child. 1960 Aug;100:208–211. doi: 10.1001/archpedi.1960.04020040210008. [DOI] [PubMed] [Google Scholar]
  2. BECKMANN R., BILLICH C. [The liver in Erb's progressive muscular dystrophy. (Biochemical and morphological findings)]. Med Welt. 1962 May 12;19:1085–1094. [PubMed] [Google Scholar]
  3. BEKENY G., KRAFT F., LANG S. [The use of durabolin (19-nor-androstenolone phenylpropionate) in the therapy of progressive muscular dystrophy]. Nervenarzt. 1960 Mar 20;31:118–123. [PubMed] [Google Scholar]
  4. BERNESKE G. M., BUTSON A. R., GAULD E. N., LEVY D. Clinical trial of high dosage vitamin E in human muscular dystrophy. Can Med Assoc J. 1960 Feb 20;82:418–421. [PMC free article] [PubMed] [Google Scholar]
  5. BROWN I. A., JAMES E. M. Nandrolone-phenpropionate in progressive muscular dystrophy. Arch Pediatr. 1961 Nov;78:421–431. [PubMed] [Google Scholar]
  6. BURDETTE W. J. Nucleotide levels in human cardiac muscle. Am Heart J. 1957 Nov;54(5):746–752. doi: 10.1016/0002-8703(57)90429-5. [DOI] [PubMed] [Google Scholar]
  7. COIRAULT R., HERSCHBERG A. D., DAMASIO R., RIGAL J., ALLIOT B., BISSIERE H. [Myopathies. Simultaneous registration of the agonist-antagonist muscular pair by the global electromyographic method. Abnormalities encountered in myopathic subjects, therapeutic results (P.T.U. and Md-2028)]. Presse Med. 1961 Dec 2;69:2373–2375. [PubMed] [Google Scholar]
  8. COIRAULT R., LEVY J., MICHEL-BER E., MASBERNARD A., DESCLOS DE LA FONCHAIS S., MAZINGANT F. [Uridine-5-triphosphoric acid in therapeutics. 1. Treatment of neurogenic muscular atrophy]. Presse Med. 1960 Jun 18;68:1127–1129. [PubMed] [Google Scholar]
  9. FLEISHER G. A., WAKIM K. G. Transaminase in canine serum and cerebrospinal fluid after carbon tetrachloride poisoning and injection of transaminase concentrates. Proc Staff Meet Mayo Clin. 1956 Nov 28;31(24):640–648. [PubMed] [Google Scholar]
  10. GOLDSZTAJN M. [Adenosinetriphosphoric acid therapy of progressive muscular dystrophy]. Neurol Neurochir Psychiatr Pol. 1962 Mar-Apr;12:219–221. [PubMed] [Google Scholar]
  11. JONES N. R., MURRAY J. The acid-soluble nucleotides of codling (Gadus callarias) muscle. Biochem J. 1960 Dec;77:567–575. doi: 10.1042/bj0770567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. KREBS H. A., KORNBERG H. L., BURTON K. A survey of the energy transformations in living matter. Ergeb Physiol. 1957;49:212–298. [PubMed] [Google Scholar]
  13. KUBERSKI Z., SULAT H. Wyniki leczenia hydrazydem kwasu izonikotynowego stwardnienia wieloogniskowego i dystrofii mieśniowej postepujacej typu Erba. Neurol Neurochir Psychiatr Pol. 1957 Mar-Apr;7(2):235–238. [PubMed] [Google Scholar]
  14. LEYBURN P., THOMSON W. H., WALTON J. N. An investigation of the carrier state in the Duchenne type muscular dystrophy. Ann Hum Genet. 1961 May;25:41–49. doi: 10.1111/j.1469-1809.1961.tb01495.x. [DOI] [PubMed] [Google Scholar]
  15. MORRELL R. M. Abnormal hepatic tests in muscular disease. AMA Arch Intern Med. 1959 Jul;104(1):83–90. doi: 10.1001/archinte.1959.00270070085011. [DOI] [PubMed] [Google Scholar]
  16. PEARSON C. M., CHOWDHURY S. R., FOWLER W. M., Jr, JONES M. H., GRIFFITH W. H. Studies of enzymes in serum in muscular dystrophy. II. Diagnostic and prognostic significance in relatives of dystrophic persons. Pediatrics. 1961 Dec;28:962–970. [PubMed] [Google Scholar]
  17. PINCHOT G. B. A polynucleotide coenzyme of oxidative phosphorylation. J Biol Chem. 1957 Nov;229(1):1–9. [PubMed] [Google Scholar]
  18. RUSKIN S. L., WILEY B. C. Contributions to the study of nerve and muscle interrelationship; studies in the pathologic physiology of poliomyelitis. Int Rec Med Gen Pract Clin. 1956 May;169(5):274–279. [PubMed] [Google Scholar]
  19. SCHAPIRA F., DREYFUS J. C., SCHAPIRA G. [The length of stay in the plasma of aldolase in the rabbit: study aided by aldolase labelled with radioactive iodine]. Rev Fr Etud Clin Biol. 1962 Oct;7:829–832. [PubMed] [Google Scholar]
  20. SHARRARD W. J. Muscle recovery in poliomyelitis. J Bone Joint Surg Br. 1955 Feb;37-B(1):63–79. doi: 10.1302/0301-620X.37B1.63. [DOI] [PubMed] [Google Scholar]
  21. SIBLEY J. A., FLEISHER G. A. The clinical significance of serum aldolase. Proc Staff Meet Mayo Clin. 1954 Nov 10;29(23):591–603. [PubMed] [Google Scholar]
  22. SPENCER G. E., Jr, VIGNOS P. J., Jr Bracing for ambulation in childhood progressive muscular dystrophy. J Bone Joint Surg Am. 1962 Mar;44-A:234–242. [PubMed] [Google Scholar]
  23. STELGENS P. Uber die Behandlung der Dystrophia musculorum progressiva (Erb) mit Adenosintriphosphorsäure. Dtsch Med Wochenschr. 1957 Oct 11;82(41):1761–1763. doi: 10.1055/s-0028-1116984. [DOI] [PubMed] [Google Scholar]
  24. SWINYARD C. A., DEAVER G. G., GREENSPAN L. Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil. 1957 Sep;38(9):574–579. [PubMed] [Google Scholar]
  25. THOMSON W. A. Sources of error in the biochemical diagnosis of muscular dystrophy. J Neurol Neurosurg Psychiatry. 1962 Aug;25:191–202. doi: 10.1136/jnnp.25.3.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. TRAVELL J. Assessment of drugs for therapeutic efficacy. Am J Phys Med. 1955 Feb;34(1):129–140. [PubMed] [Google Scholar]
  27. VIGNOS P. J., Jr, ARCHIBALD K. C. Maintenance of ambulation in childhood muscular dystrophy. J Chronic Dis. 1960 Aug;12:273–290. doi: 10.1016/0021-9681(60)90105-3. [DOI] [PubMed] [Google Scholar]
  28. WALD S. M., LAM R. L. Treatment of muscular dystrophy with amino acids and vitamins. Neurology. 1955 Dec;5(12):887–890. doi: 10.1212/wnl.5.12.887. [DOI] [PubMed] [Google Scholar]
  29. WALTON J. N., NATTRASS F. J. On the classification, natural history and treatment of the myopathies. Brain. 1954;77(2):169–231. doi: 10.1093/brain/77.2.169. [DOI] [PubMed] [Google Scholar]
  30. WORDEN D. K., VIGNOS P. J., Jr Intellectual function in childhood progressive muscular dystrophy. Pediatrics. 1962 Jun;29:968–977. [PubMed] [Google Scholar]
  31. WROBLEWSKI F., LADUE J. S. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med. 1956 Apr;91(4):569–571. doi: 10.3181/00379727-91-22330. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES